The immunochemical properties of apolipoprotein (apo) B have been studied in very low density lipoprotein (VLDL), (Sf 100 to 400), VLDL 2 (Sf 60 to 100), VLDL 3 (Sf20 to 60), different intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) subfractions isolated from patients with type IV hypertriglyceridemia. In these lipoproteins, we characterized the association of apo B with other apolipoproteins and the expression and immunoreactivity of several apo B epitopes close to the apo B receptor binding sites (3F5, 4G3, 3A8, and 5E11) and of other epitopes located on the apo B100-B48 common region (1D1 and 2D8). Immunoprecipitation showed that the proportion of lipoprotein particles expressing each apo B epitope increased from VLDL, to LDL*; this was more apparent with 3A8 and SE11 than with 3F5. The VLDL that were negative for apo E epitopes (60% or more of the total) were enriched in apo C. The lipoprotein particles containing apo E and/or apo C-lll decreased progressively from VLDL, (30% and 85%, respectively) to LDL 2 (10% and 25%, respectively). Similar observations were made for apo C-l and apo D, demonstrating that apolipoprotein heterogeneity is greatest in the lightest lipoproteins. By competitive radioimmunoassay, the epitope for 4G3 was equally immunoreactive in each lipoprotein subclass, and the affinity constant (Ka) of 4G3 for different lipoproteins showed little variation. In contrast, both immunoreactivity and Ka of 3A8 and 5E11 increased progressively and significantly with the increasing density of the lipoprotein subclasses. This phenomenon is correlated with the increasing binding affinity of apo B in these lipoprotein subclasses to the LDL receptor of fibroblasts. We conclude that, as the apo B-containing lipoproteins become smaller, the conformation of specific regions of apo B is modified: in the receptor binding domain, the conformation of epitope 4G3, which is mapped between residues 2980 and 3080, remains constant, while that of 3A8 and 5E11 (residues 3441 to 3568) changes progressively. We propose the theory that the change in conformation in the domain spanning residues 3441 and 3568 allows the maximum expression of epitopes 3A8 and 5E11 and of the receptor binding site. 23 The size and density heterogeneity of the apo B-containing lipoproteins appear to be introduced not only at the time of secretion of nascent lipoproteins 4 but also during catabolism, 5 the end-point of which is the cellular uptake via receptors that recognize either apo B-100 or apo E or both. 6 In the course of the intravascular transformation of VLDL, the ligand responsible for the binding of the lipo- Received March 31, 1988; revision accepted June 24, 1988. protein to the apo B/E receptor changes progressively from apo E to apo B as the particle becomes smaller, 78 and this transformation is most pronounced at the stage of VLDL 3 (Sf 20 to 60). The studies of Gianturco et al. 7 and Bradley et al. 9 have shown that the apo E-mediated affinity of the VLDL for the apo B/E receptor is dependent upon the conformation assumed by apo E on the lipoprotein and that the change in conformation is brought about by the catabolism of the VLDL. Conversely, it is thought that lipolysis of VLDL particles, which results in formation of smaller and denser lipoproteins, also causes a change in apo B conformation, which increases its affinity for the apo B/E receptor. Indeed, Schonfeld and colleagues 10 made the important observation that lipolysis of VLDL caused an increase in both the reactivity of the lipoproteins with the apo B/E receptor and their immunoreactivity with antisera against LDL apo B. Although there is good evidence that this process occurs, we have no information on how apo B conformation is modified and how this specifically affects the receptor binding site on apo B.
N ormally very low density lipoproteins (VLDL) are converted into low density lipoproteins (LDL) in the circulation by the combined actions of lipoprotein lipase and lipid transfer proteins, 1 and most of the LDL are cleared by the apolipoprotein (apo) B/E receptor. 23 The size and density heterogeneity of the apo B-containing lipoproteins appear to be introduced not only at the time of secretion of nascent lipoproteins 4 but also during catabolism, 5 the end-point of which is the cellular uptake via receptors that recognize either apo B-100 or apo E or both. 6 In the course of the intravascular transformation of VLDL, the ligand responsible for the binding of the lipo-protein to the apo B/E receptor changes progressively from apo E to apo B as the particle becomes smaller, 78 and this transformation is most pronounced at the stage of VLDL 3 (Sf 20 to 60). The studies of Gianturco et al. 7 and Bradley et al. 9 have shown that the apo E-mediated affinity of the VLDL for the apo B/E receptor is dependent upon the conformation assumed by apo E on the lipoprotein and that the change in conformation is brought about by the catabolism of the VLDL. Conversely, it is thought that lipolysis of VLDL particles, which results in formation of smaller and denser lipoproteins, also causes a change in apo B conformation, which increases its affinity for the apo B/E receptor. Indeed, Schonfeld and colleagues 10 made the important observation that lipolysis of VLDL caused an increase in both the reactivity of the lipoproteins with the apo B/E receptor and their immunoreactivity with antisera against LDL apo B. Although there is good evidence that this process occurs, we have no information on how apo B conformation is modified and how this specifically affects the receptor binding site on apo B. Total cholesterol, triglycerides cholesterol levels in lipoproteins, and LDL apo B levels are expressed as mg/dl and measured as indicated in the Methods section. Total cholesterol and triglyceride were measured in the blood samples used for the present studies, while cholesterol levels in lipoproteins and LDL apo B levels were determined on a previous sampling.
The lipoproteins of patients 1 to 7 were used in immunoprecipitations, those of patients 6 to 14 in competitive radioimmunoassay (RIA); the lipoproteins of patients 14 to 16 were used for lipid composition analysis, and those of patients 9 and 17 for calculation of Ka.
BMI=body mass index, DM=diabetes mellitus, OH=oral hypoglycemic agents, CPIB=clofibrate, GFZ=gemfibrozil, HBP=high blood pressure, LDL=low density lipoproteins, VLDL=very low density lipoproteins, HDL=high density lipoproteins.
epitopes of apo B when this apolipoprotein is associated with lipoproteins of different sizes and densities from VLDL, (Sf 100 to 400) to LDL (Sf 0 to 12). Several well-defined epitopes identified by antibodies 3F5, 4G3, 3A8, and 5E11, which have been shown to be close to the receptor binding site of apo B, 1112 have been evaluated and compared to other epitopes, such as those reacting with Mabs 1D1 and 2D8, which are localized on the sequence common to apo B-100 and apo B-48. 13 In contrast to VLDL from hypertriglyceridemic patients, VLDL isolated from normal subjects do not suppress the activity of HMG-CoA reductase in fibroblasts. 141516 VLDL, therefore, may be functionally heterogeneous depending on the clinical status of the donor. Taking these observations into account, we elected to study the expression of apo B epitopes in lipoprotein subclasses isolated from selected patients with a well-documented type IV hyperlipoproteinemia. The patients have a moderate hypertriglyceridemia and, in most cases, hyperapobetalipoproteinemia. 17 A preliminary report on part of these studies was presented earlier.
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Methods
Patients
Seventeen subjects, 14 men and 3 women, ages 30 to 63 years (mean±SD, 48.2±10), gave their informed consent and donated blood for this study. They were selected among patients followed at the lipid clinic for moderate endogenous hypertriglyceridemia (type IV) as defined by concentrations of triglycerides between 160 and 900 (392±183). Their biological characteristics, including the lipoprotein profile at, or close to, the time of sampling, are presented in Table 1 . In all instances, plasma VLDL cholesterol was greater than 35 mg/dl (71 ±24) and LDL cholesterol lower than 180 mg/dl (128±32). Twelve subjects had hyperapobetalipoproteinemia with LDL-apo B greater than 125 mg/dl, 17 and seven had hypoalphalipoproteinemia (high density lipoprotein, HDL, <30 mg/dl). None had the E2/2 apo E phenotype. All but one (#16) were on a lipid-lowering diet when blood was taken, two were on clofibrate, two were on gemfibrozil, and five were being treated for mild noninsulin-dependent diabetes, four of them with an oral hypoglycemic agent. Three subjects were treated for arterial hypertension with a thiazide diuretic, a betablocker, or both. Five were obese with a body mass index (BMI, mass/height squared) greater than 30. Thyroid function was normal in all subjects and there was no excess alcohol intake. All but one (#14, an Asian) were Caucasian.
dialyzed against phosphate-buffered saline (PBS) containing EDTA (1 mM) and NaN 3 (0.02%), and these were stored at 4°C. Two different approaches were used for the preparation of lipoprotein subfractions, both of which were based on the method of Lindgren et al.
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Method 1 Sequential floatation of plasma lipoproteins (Sf > 400-free) in a discontinuous salt gradient 19 with a Beckman rotor SW41 gave VLDL, (Sf 100 to 400), VLDL 2 (Sf 60 to 100), and VLDL 3 (Sf 20 to 60). The remaining intermediate density lipoproteins (IDL) were isolated by centrifugation of the infranatant adjusted at d=1.019 g/ml and the LDL by centrifugation at d=1.063 g/ml, both in a Beckman rotor 70 Ti. In two patients, the LDL were first isolated between densities of 1.019 and 1.071 g/ml and centrifuged again in a discontinuous salt gradient as described by Teng et al. 20 to yield the subfractions LDL,, LDL 2 , and LDL 3 . These methods were used to prepare the lipoprotein subfractions that were tested in competitive radioimmunoassays.
Method 2
Plasma (Sf > 400-free) was adjusted at d=1.055 g/ml and centrifuged in a rotor 70.1 Ti (45 000 rpmx22 hours at 12°C). After dialysis against PBS containing EDTA (1 mM) and NaN 3 (0.02%), an aliquot of the lipoproteins of d=1.055 g/ml was used for labeling with 125 I as described below. Both labeled and cold lipoproteins were then separated by centrifugation in a discontinuous salt gradient according to the method of Lindgren et al. 19 to obtain VLDL, (Sf 100 to 400), VLDL 2 (Sf 60 to 100), and VLDL 3 (Sf 20 to 60). The density of the infranatant was then raised to d=1.030 g/ml and centrifuged in a rotor 70.1 Ti (45 000 rpmx20 hours at 12°C, to yield a composite fraction, IDL+LDL,. Finally, the infranatant was raised to d=1.050 g/ml and centrifuged in a rotor 70.1 Ti (45 000 rpmx22 hours at 12°C) to give the LDL 2 . These lipoprotein fractions were used in the immunoprecipitation experiments and in the determination of Ka.
Labeling of Lipoproteins
The lipoproteins were first concentrated to about 10 to 15 mg protein/ml by vacuum dialysis and were labeled by the iodine monochloride method of McFarlane 21 as modified by Bilheimer et al. 22 Typically, between 0.5 and 1.5 mg of lipoprotein protein were labeled with 125 I (2.25 mCi) and ICI (33.3 nmol) and were then separated by chromatography on a column (10x1 cm) of Sephadex G-25. The labeled lipoprotein peak was usually isolated in 1 ml.
Immunoprecipitation of Labeled Lipoproteins
Pansorbin cells (pickled Staphylococcus aureus cells, Calbiochem-Behring, La Jolla, CA) were washed three times with 1 % BSA, 1 mM EDTA, and 0.02% NaN 3 , in PBS pH 7.2 (reaction buffer). Between washes, the cells were centrifuged at 3000 g for 15 minutes at 4°C. The prewashed Pansorbin was armed with rabbit antimouse immunoglobulin (Cedarlane Laboratories, Hornsby, Ontario) at a concentration sufficient to saturate the Pansorbin cells (0.25 ml antiserum/g Pansorbin), and the mixture was left to incubate for 24 hours at 4°C. 23 The armed cells were washed three times as described above.
In addition to the various Mabs, we used an unrelated Mab (2H2, antirat atrial natriuretic factor) to determine nonspecific precipitation. Typically, antibody dilutions were prepared in 250 /xl of reaction buffer, were mixed with 25 /J,I of labeled lipoprotein (50 ng protein, about 10 000 cpm), and were incubated for 18 hours at 4°C. Pansorbin cells armed with antimouse IgG (50 /xl) were then added to the mixture, which was incubated for another 4 hours at 4 C C. When a rabbit polyclonal antiserum was used as in the case of apo C-lll, unarmed Pansorbin was utilized for precipitation. The Pansorbin-lipoprotein complex was spun down by centrifugation at 3000 g for 15 minutes; the pellet was washed once with 250 ^\ of reaction buffer and counted in a gamma counter. Several controls, in which antibody or Pansorbin was omitted, were included. To precipitate the lipoprotein, trichloroacetic acid (TCA) was added to a final concentration of 12% and the pellet was sedimented by centrifugation at 13 000 g for 10 minutes, was washed as above, and was then counted. The results were expressed as percentages of radioactivity bound, B/Box100, where B=cpm precipitated by Pansorbin cells and Bo=cpm precipitated in controls by TCA. In these experiments, the nonspecific precipitation evaluated with an irrelevant Mab was constant in each lipoprotein subclass. In four distinct preparations with different donors, it was found to be 6.2%±2.4%, 4.8%±1.5%, 4.9%±1.7%, and 5.8%±1.8% for VLDL,, VLDL 2 , VLDL 3 , and IDL, respectively. Because each antibody is susceptible to different nonspecific interactions with the labeled ligand and because the nonspecifically precipitated antigen could also have been susceptible to specific immunoprecipitation, the control values for nonspecific interactions have their own informative interest. Accordingly, they are reported for each experiment and have not been subtracted.
Determinations of Affinity Constants
Competitions between 125 l-labeled and cold lipoproteins were used to determine the affinity constants of the different anti-apo B Mabs for each apo B-containing lipoprotein subtraction. Serial doubling dilutions of competing unlabeled lipoproteins were prepared in volumes of 100 fi\ to which were added 50 /JL\ of 125 l-lipoprotein (50 ng protein, about 10 000 cpm) and 100 til of the Mab at the dilution required for approximately half-maximum binding. The dilution buffer was the reaction buffer as defined for immunoprecipitations. Maximum binding in the absence of competing antigen was also determined. The tubes were incubated at 4°C. The Pansorbin-lipoprotein complex was centrifuged, washed, and counted as described above. The affinity constants, Ka, of the Mabs were calculated from the formula:
where C is the molar concentration of competing antigen required for 50% inhibition of antibody binding to the labeled lipoprotein, L is the molar concentration of added labeled lipoproteins, and b is the maximum binding of the labeled lipoprotein in the absence of competitor, calcu-lated as the proportion of the radioactivity bound, B/Bo, as above. The molar concentration of lipoproteins were calculated from the apo B protein mass of each fraction.
Competitive-Radioimmunoassays
Solid phase radioimmunoassay (RIA) was performed in Immulon II removawells (Dynatech Laboratories, Alexandria, VA) essentially as described earlier. 1120 The wells were coated by an overnight incubation with 200 /xl of reference LDL (30 /xg/ml in 5 mM glycine, pH 9.2, obtained between d=1.030 and d=1.050 g/ml from a normolipemic donor), and subsequently saturated by incubation for 1 hour with 250 ix\ of 1% BSA, pH 7.4. Each Mab, which was appropriately diluted in BSA-PBS, was incubated overnight with dilutions of either the reference LDL or the various apo B-containing lipoproteins at final concentrations ranging from 0.1 to 10 /xg apo B protein/ml in BSA-PBS in disposable culture tubes. Aliquots (200 /xl) of these mixtures were then transferred to the coated and saturated wells, which had been rinsed with 0.15 M NaCI containing 0.025% Tween 20. The wells were incubated overnight and again rinsed with the Tween-saline solution. 125 l-labeled rabbit antimouse IgG 11 diluted in BSA-PBS was added to the wells (200 /J representing about 60 000 cpm) and was incubated overnight. The wells were washed with the Tween-saline solution and were counted for radioactivity. The intra-assay coefficent of variation was less than 10% for each Mab.
Antibodies against Human Apolipoproteins
All procedures used to obtain antibodies in animals were done in accordance with the regulations of our institutional committee on animal care. The Mabs against apo B used in these studies were obtained by immunization of mice with LDL. 11 The specificity of these Mabs and the identification of their epitopes have been described in several reports. 111213 The properties of the Mabs against apo E 25 and against apo D 26 have been reported earlier. Mab 3D7 was obtained from mice immunized with chylomicrons. It reacted with purified C-l in RIA; by immunoblots it was shown to react with a protein of 6500 daltons on SDS-gel electrophoresis, with a pi of about 7.5 on isoelectric focusing and with an apolipoprotein displaying the characteristic migration of apo C-l on alkaline gel electrophoresis in the presence of urea. Because this Mab did not react with any other apolipoprotein, we concluded that 3D7 is directed against apo C-l. The rabbit polyclonal antisera against apo C-l 11 and apo B were kind gifts from Walter J. McConathy of 
Lipoprotein Binding to Human Fibroblasts
Human skin fibroblasts were obtained from a forearm skin biopsy and the receptor binding experiments were conducted as previously described. 11 Specifically, cells were grown in 35 mm dishes (Costar, Cambridge, MA) containing 2 ml of DMEM supplemented with 10% (vol/ vol) fetal bovine serum. Before reaching confluency, cells were rinsed with 1 ml of sterile PBS and were incubated for 48 hours in DMEM supplemented with 10% (vol/vol) of lipoprotein-deficient serum (medium A). Before the experiment, the cells were cooled at 4°C for 30 minutes, and the medium was replaced by 0.7 ml of cold medium A containing HEPES (pH 7.4) and I-LDL were performed as described earlier.
11 Specific binding was measured by subtracting the amount of 125 I-LDL bound in the presence of an excess LDL (500 /j,g protein/ml).
Analyses
Protein was measured by the method of Lowry et al. 27 using BSA as a standard and apo B by the method of Kane et al. 2 8 2 9 Plasma cholesterol 30 and triglycerides 31 were measured enzymatically with an autoanalyzer. The plasma lipoprotein cholesterol content was determined after separation of the lipoproteins according to the Lipid Research Clinics Protocol, 32 and apo E phenotype was determined by isoelectric focusing. 33 The lipid composition of the lipoproteins was measured by gas-liquid chromatography.
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Results
The patients who donated blood for this study were clinically and biochemically characterized (see the Methods section and Table 1 ). The average composition of the lipoproteins from three patients representative of this group (patients 14, 15, and 16 in Table 1 ) is presented in Table 2 and agrees with the expected values for the different density subclasses. 1535 The major changes in lipid composition were the progressive decrease in triglyc- Values are expressed as the mean percentages±SD (n=3) by weight of total lipids as measured by gas liquid chromatography and of proteins.
VLDL=very low density lipoproteins, IDL=intermediate density lipoproteins, LDL=low density lipoproteins. 
75+1
The values are the percents of the radioactivity precipitated by each antibody at the plateau relative to the TCA-precipitable radioactivity, means and SD of three preparations from different donors. The nonspecific precipitation obtained with an irrelevant Mab 2H2 varied from 2% to 8%, with an average of 5%.
"Significantly different from the corresponding value for 3F5 (p=0.05).
Apo=apolipoprotein, VLDL=very low density lipoproteins, IDL=intermediate density lipoproteins.
erides and the concomitant increase in cholesteryl esters that characterize the increase in hydrated density of the VLDL and their transformation in LDL.
Immunoprecipitation of Apolipoprotein B-contalning Lipoproteins
To evaluate the proportion of the different VLDL subclasses and IDL that expresses specific apo B epitopes, we first studied these lipoproteins in three patients (Table  1 , subjects 5, 6, and 7). The lipoproteins of d<1.019 g/ml were isolated, were labeled with 1 2 5 I, and were fractionated into VLDL,, VLDL 2 , VLDL 3 , and IDL. Each labeled subfraction was subjected to immunoprecipitation by individual anti-apo B Mabs and antimouse IgG-Pansorbin under conditions of antibody excess as described in the Methods section. The results are summarized in Table 3 . While the percentage of lipoproteins immunoprecipitated varied between subjects, for each patient, and for each Mab, we observed that the proportion of lipoproteins expressing the different epitopes increased regularly with the increasing hydrated density of the lipoproteins. While all the epitopes of apo B that we tested were similarly expressed on about 75% or more of the IDL, the epitopes for 3A8 and 5E11 as compared to 1D1, 2D8, and 3F5 were expressed on fewer VLDL, (Table 3) .
To investigate this difference in epitope expression in greater detail, immunoprecipitations of lipoprotein subtractions with 3F5 and 3A8 were compared in four other patients (subjects 1,2,3, and 4, Table 1 ). The lipoproteins of d<1.055 g/ml were isolated; were labeled with 125 I; were fractionated by sequential floatation into VLDL,, VLDL 2 , VLDL 3 , IDL+LDL,, and LDL 2 ; and were individually immunoprecipitated with each Mab as described above (Table 4) . Again we noted that the proportion of lipoproteins that expressed the antigenic determinants for 3F5 and 3A8 increased progressively as the hydrated density of the fractions increased from VLDL, to LDLa. In addition, the proportion of lipoproteins expressing the epitope for 3A8 compared to those expressing the epitope for 3F5, was significantly smaller in VLDL,, VLDL 2 , and VLDL3, while there was no such difference in the LDL fraction (Table 4) .
To evaluate whether the epitopes for 3F5 and 3A8 were expressed on the same particles, immunoprecipitation by a combination of these Mabs was carried out. Combination of 3F5 with 3A8 gave a small and nonsignificant increase as compared to 3F5 alone in the immunoprecipitation of each lipoprotein subclass (Table 5 ). In contrast, the combination of 3F5 and 3A8, compared to 3A8 alone, resulted in a significantly higher immunoprecipitation for VLDL,, VLDL 2 , and VLDL 3 , but not for IDL+LDL, and LDL 2 (Table 6 ). We can, therefore, conclude that, in all the lipoprotein subclasses, each particle that expresses the epitope for 3A8 also expresses that for 3F5, but that within the VLDL range, there are lipoproteins that express the epitope for 3F5 but not that for 3A8. It should also be noted that in all immunoprecipitations, the epitope for 5E11 was expressed on the same lipoproteins and to the same extent as the epitope for 3A8 (not illustrated). Values are the percents of the radioactivity precipitated by each combination of antibodies at the plateau relative to the TCA-precipitable radioactivity, means and SD of four preparations from different donors. The nonspecific precipitation with Mab 2H2 varied from 4% to 7% (mean, 6±1%).
Table 4. Immunoprecipitation of Lipoprotein Subclasses by Antibodies against Apollpoproteins E, C-l, C-lll, and D
'The first antibody was 3F5. VLDL=very low density lipoprotein, IDL=intermediate density lipoprotein, LDL=low density lipoprotein.
Association of Other Apolipoproteins with Apolipoprotein B-containing Lipoproteins
Apo B-containing lipoproteins are known to contain several other apolipoproteins that are believed to serve in the modulation of their metabolism. 2936 It was, therefore, of interest to quantify the different apolipoproteins associated with apo B and, in particular, to evaluate whether specific epitopes of these apolipoproteins were expressed on the same particles as those expressing the epitopes for 3F5 and 3A8. In agreement with the results of others who reported that apo E concentration decreases from VLDL to LDL, 3738 we observed that the percentages of lipoproteins that express two distinct apo E epitopes decreased progressively in each subtraction from VLDL, to LDL 2 (Table 4) . While this decrease as a function of lipoprotein density was observed in each patient studied, the maximum percentage of VLDL that express these apo E epitopes varied greatly between subjects. This observation indicates an important variation in the immunoreactive apo E concentration in VLDL, which ranged from 20% to 65% of the particles, with an average of 48% for the 10 subjects studied. The apo E epitopes for both 1D7, which is localized at residue 139 to 169 close to the receptor binding site, 39 and 6C5, which is localized at the amino terminus, 40 are expressed in the same proportion of particles in all lipoprotein fractions tested (Table 4) . Moreover, the combination of 1D7 and 6C5 precipitated the same percentage of lipoproteins as either Mab alone, indicating that the two epitopes are also expressed on the same particles (not illustrated).
Nearby all of the lightest VLDL particles contained apo C-lll (85%) and, as expected from the literature, 29 -36^ the relative number of lipoproteins that contain apo C-lll fell progressively from VLDL, to LDL 2 (Table 4) ; but it is important to note that about 25% of the LDL 2 particles contained at least one molecule of apo C-lll. Similar observations were made with apo C-l and apo D; the proportions of lipoproteins containing these apolipoproteins also decreased with increasing lipoprotein density, but again a highly significant proportion of the LDL 2 particles still contained these two apolipoproteins. It would appear that the proportion of lipoproteins containing apo C-l varies from subject to subject because, in two other patients not included in the results of Table 4 , we noted that 85% and 40% of their respective VLDL contained apo C-l. The immunoprecipitation by combination of 3F5 and anti-apo E (1D7, 6C5) or anti-apo C-l (3D7) or anti-apo D (4E11) did not result in any significant increase in the proportion of lipoprotein precipitated (Table 5) . Similar results were obtained when the same combination of Mabs was tested with 3A8 instead of 3F5 (Table 6) . Therefore, in each density subclass, all the lipoproteins that expressed the determinants for apo E, apo C-l, and apo D also expressed the epitopes corresponding to 3A8 and 3F5. In contrast, the combination of anti-apo C-lll with either 3F5 (Table 5) or 3A8 (Table 6 ) resulted in significant increases in the percentage of immunoprecipitated lipoproteins in all the VLDL subclasses.
The apolipoprotein composition of lipoproteins that were not precipitated by Mabs against apo B, C-lll, and E was evaluated by SDS-gel electrophoresis and counting of the radioactivity associated with specific fractions (Table  7) . The VLDL used in these experiments were isolated from three different patients. Mab 1D1, which reacts with The conditions were the same as in Table 5 . *The first antibody was 3A8. VLDL=very low density lipoproteins, IDL=intermediate density lipoproteins, LDL=low density lipoproteins. 
'Labeled very low density lipoproteins (VLDL) were immunoprecipitated by different Mabs as described under Methods. The supernatants from these precipitations were delipidated and analyzed by SDS-gel electrophoresis; the radioactivity associated with specific apolipoproteins was counted and compared to that present in the control treated with an irrelevant Mab.
fThe percent of VLDL remaining after the immunoprecipitation as calculated under Methods from the ratio of radioactivity in the supernatant and the initial radioactivity.
Antibodies MB-24 and C15, which are specific for apo B and apo C-lll, respectively, were gifts from Linda Curtiss from La Jolla, CA (Mab MB-24) and from Jean-Charles Fruchart, Lille, France (C15).
Apo=apolipoproteins.
an epitope of apo B located between residues 401 and 582 and which immunoprecipitated between 65% and 73% of VLDL subtractions in earlier experiments, was compared to another Mab anti-apo B identified as MB-24, 41 which reacts against a very close epitope (residues 97 to 689). Both antibodies displayed similar properties, although 1D1 precipitated somewhat less VLDL, since 23%, 27%, and 25%, respectively, of the three VLDL preparations remained in solution ( Table 7) . The VLDL that were not precipitated by 1D1 were relatively enriched in apo E and apo C-lll. The anti-apo E, 6C5, could precipitate 32%, 55%, and 70%, respectively, of the three VLDL preparations (Table 7) . In each case, the VLDL remaining in solution were significantly enriched in apo C and still contained 88%, 55%, and 40% of the radioactivity initially present in these apoproteins. In contrast, the anti-apo C-lll could precipitate most of the VLDL (88% to 91%), and the VLDL remaining in solution seemed to contain similar percentages of each apolipoprotein associated with the starting VLDL ( Table 7) .
Competitive Radioimmunoassays of Apolipoprotein B-containing Lipoproteins
For these experiments, the plasma of seven patients (6, 7, 8, 9,10,11, and 14 in Table 1 ) were first centrifuged by sequential floatation to yield VLDL,, VLDL 2 , VLDL 3 , IDL, and LDL. In two other patients (12 and 13 in Table 1 ), another plasma aliquot was used to prepare LDL (1.019 to 1.071 g/ml), which was subsequently separated into LDL,, LDL 2) and LDL 3 by density gradient centrifugation. 20 The immunoreactivities of the different lipoprotein subfractions from the nine patients were then compared by competitive RIA to a reference, narrow-cut LDL (1.020 to 1.050 g/ml) from a normolipemic donor and with the different Mabs against apo B LDL .
Typical results obtained with the lipoproteins of one patient and with the different Mabs are presented in Figures 1 and 2 . The immunoreactivity of apo B in the different VLDL subclasses and in IDL with Mabs 1D1 and 2D8 was virtually identical, but was significantly greater than that of the LDL subfractions (Figure 1) . The same observations were made qualitatively with the lipoproteins of the nine different patients studied, although there was some variation among patients in the magnitude of the difference in immunoreactivity between VLDL and LDL.
Significantly different results were obtained with Mabs 4G3,3A8, and 5E11 as, with each of these antibodies, the apo B in LDL subfractions was more immunoreactive than VLDL apo B (Figure 2) . The difference was minimal with 4G3, and with this antibody there was no significant difference in immunoreactivity between VLDL subclasses. In contrast, the immunoreactivity of apo B with Mabs 3A8 and 5E11 increased significantly and progressively with the increasing density of the lipoproteins containing apo B from VLDL, to IDL, and LDL,. The same observations were made with the lipoprotein subfractions of each of the nine patients studied. The immunoreactivity of the LDL subfractions with Mabs 3A8 and 5E11, which were studied in only two patients (including the one illustrated here), did not vary significantly. 
Affinity Constants of Anti-apoprotein B Mabs for Different Apoprotein B-containing Lipoproteins
The expression of apo B epitopes in each lipoprotein subclass was characterized by equilibrium competitive inhibition assays in fluid phase, where the ability of each subfraction to compete with the autologous labeled subfraction for binding to each Mab was evaluated. Full displacement of the labeled lipoprotein by the cold counterpart was observed in all cases but three, where the affinity constants (Ka) could not be measured. The Ka were calculated as described in the Methods section, and the results are summarized in Table 8 . Antibodies 1D1, 2D8, 3F5, and 4G3 were characterized by similar Ka in the range of 10 9 M~\ which vary with the different lipoprotein subclasses, whereas 3A8 and 5E11 had an average of a 10-fold lower Ka for the same lipoprotein subclasses. This relative lower affinity of 3A8 and 5E11 for their epitopes, as compared to the other anti-apo B Mabs, corroborates and may explain the lower proportion of VLDL subclasses that are immunoprecipitated by 3A8 and 5E11 in comparison to the other Mabs (Tables 3 and  4) . However, the significantly lower Ka of 3A8 for IDL+LDL, and Competitive RIA generally afforded a more sensitive assay for the comparison of epitope immunoreactivities in the different subclasses of apo B-containing lipoproteins as indicated by the good concordance between the affinity constants and the immunoreactivites of the subfractions in RIA. The Ka of 3A8 for the apo B-containing lipoproteins increased together with their increase in hydrated density and does corroborate and explain the progressive increase in immunoreactivity of the lipoproteins from VLDL, to LDL, that was noted with 3A8 in competitive RIA (Figure 2 ). It is also significant that, with antibody 4G3, there was no significant change in either Ka (Table 8) or immunoreactivity in competitive RIA (Figure 2 ) as a function of the hydrated density of the apo B-containing lipoproteins. However, Mabs 1D1 and 2D8 had similar affinity constants for VLDL and LDL subtractions (Table 8 ), but they reacted better with VLDL apo B than with LDL apo B in competitive RIA (Figure 1) . Finally, the affinity constant of 3F5 changed little from VLDL, to LDL 2 , but this antibody was not studied in competitive RIA.
Binding of Apolipoprotein B-containing Lipoproteins to LDL Receptor
The ability of VLDL,, VLDL 2> VLDL 3 , and IDL+LDL, isolated from two different donors to compete with 125 I-LDL for binding to the LDL receptor of human fibroblasts was evaluated, as described in the Methods section, in the presence or absence of antibody 1D7 to inhibit the binding contribution of apo E to the receptor. In the presence of 1D7 and at a constant level of apo B, the capacity of apo 
IDL, LDL,
Fibroblasts were incubated at 4°C as described under Methods in the presence of 125 I-LDL (3 M9 protein/ml) in the presence or absence of lipoprotein subtractions (5 /ng apo B protein/ml), which had been pre-incubated (or not) with Mab 1D7 (30 /xg protein/ml). Control experiments, which gave 6.03+0.23 and 7.43+0.60 ng 125 I-LDL bound to receptors in the presence and in the absence of 1D7, respectively, were carried out.
Apo=apolipoproteins, VLDL=very low density lipoproteins, IDL=intermediate density lipoproteins, LDL=low density lipoproteins.
B-containing lipoproteins to bind to the LDL receptor increased progressively as their density increased (Table  9 ). However, in the absence of 1D7 to block the contribution of apo E, there was no significant difference in the affinity of VLDL subclasses to bind to the receptor.
Discussion
The physiopathology of type IV hyperlipoproteinemia is usually the result of an overproduction of VLDL coupled with a concomitant defect in the clearance of one or another lipoprotein species, often caused by a defect in the lipolytic system. 42 Most of the patients studied here also have a moderate hyperapobetalipoproteinemia, which is the accumulation of denser than normal LDL particles; 17 that is, because each LDL contains one molecule of apo B, they accumulate more LDL particles with lower cholesterol content. This condition is usually the result of a mild defect in the clearance of LDL linked with overproduction of VLDL. The patients who donated blood for our studies represent a well-defined group in terms of hypertriglyceridemia, VLDL cholesterol levels, LDL cholesterol and apo B levels, and none was homozygous for an apo E 2 phenotype. The lipid composition of their lipoprotein subtractions corresponds generally to that reported by others 35 for these subclasses of Sf 10 to 400 lipoproteins in type IV persons with moderately severe hypertriglyceridemia.
It is well-known that lipolysis induces a gradual transfer of apo C-ll, apo C-lll, and apo E from VLDL to high density lipoprotein (HDL). However, this process is incomplete, as both the apo C-lll pool 43 and the apo E pool 44 are heterogeneous and are not entirely available for transfer. The ratio of apo C-lll to apo E 4546 and the conformation of apo E in VLDL 916 have been shown to modulate the interaction of VLDL and their remnants with celluar receptors and are important determinants of the fate of these lipoproteins. In this context, the immunoprecipitation studies of VLDL subtractions with antibodies against apo B and other apolipoproteins provide original and important information on the nature of the apolipoproteins associated with apo B and on the heterogeneity of these lipoproteins. The immunoprecipitation assay that we used is essentially a scaled-up immunoassay, since the procedure follows the same steps as in a fluid-phase double-antibody assay. This method is sensitive, nondisruptive, and applicable to small samples, and it provides better recovery than immunoadsorbers. We have previously validated this technique in the immunoprecipitation of LDL and solubilized apo B 23 and of HDL apo A-l and apo A-ll. 47 -« It should be noted that the immunoprecipitation assay with Mabs provides an estimate of the minimum percentage of lipoproteins that express a given epitope but does not rule out that the other lipoproteins may contain the antigen without expressing the specific epitope. With these reservations in mind, it is nevertheless significant that, on the average, only one-third of the VLDL expressed the two apo E epitopes for 1D7 and 6C5 and that this proportion was further reduced by half for VLDL 3 and LDL, ( Table 4 ). As our immunoprecipitation experiments do not provide information on the number of apo E molecules per particle, it is of interest that Bradley and colleagues 16 calculated that in type IV subjects, VLDL 2 contains 2 to 3 molecules of apo E per particle as compared to 0.2 to 0.3 molecule per particle for IDL. This means that between one-third and two-thirds of the VLDL particles (the range of our immunoprecipitations between subjects) contain immunodetectable apo E and that each of these particles contains several molecules of apo E (probably in the range of four or more). In contrast, the apo E content of IDL was calculated to be between 0.2 and 0.3 molecule per particle, 16 a value that is close to the percentage of LDL, which expresses the epitopes for 1D7 and 6C5. This would imply that most of the VLDL, and VLDL 2 that contain multiple molecules of apo E are removed from the circulation before reaching the density of LDL.
The observation that the lipoproteins that are not immunoprecipitated by 1D1 are relatively enriched in apo E and apo C peptides (Table 7) is of interest and may be interpreted as evidence for either VLDL species in which the presence of apo E or apo C mask certain epitopes, such as 1D1. The immunoprecipitation of VLDL with an anti-apo E Mab also supports the notion of the compositional heterogeneity of these lipoproteins and demonstrates the existence of VLDL that are rich in apo C and lack apo E. The proportion of these lipoproteins may vary significantly between subjects, but it accounts for at least 30% of VLDL in type IV hyperlipoproteinemia. Similar observations have been made recently by others 49 who used immunoprecipitations with polyclonal antisera combined with electroimmunoassays. The immunoprecipitation studies reported here show that the proportion of the lipoproteins expressing each of the studied apo B epi- topes increases as the hydrated density of lipoproteins increases (Tables 3 and 4) . A priori, this would indicate that as the protein-to-lipid ratio increases and the size of the lipoprotein decreases, the conformation of multiple domains of apo B is changed to give a more immunoreactive apo B. However, when we take into account the expression of individual epitopes on lipoproteins as measured by immunoprecipitation, the relative immunoreactivity as evaluated by competitive RIA, and the affinity constants of each Mab, it is clear that lipolysis and other remodeling processes of apo B-containing lipoproteins differentially modify individual regions of apo B.
The epitopes for 1D1 and 2D8, which have been mapped on both apo B-100 and apo B-48 between residues 401 to 582 and 1297 to 1480 respectively (Figure 3) , are expressed on a smaller proportion of VLDL, than LDL (Table 3) , and the proportion of lipoproteins expressing these epitopes increased with increasing densities. Because the Ka of 1D1 and 2D8 for VLDL, and VLDL 2 is equal to or greater than that for the denser lipoproteins, the lower proportion of VLDL compared to LDL that is precipitated by these Mabs truly reflects the lower proportion of VLDL that expresses these epitopes, and not a change in affinity. The competitive RIA also support this conclusion; we observed a greater immunoreactivity of VLDL compared to LDL with both 1D1 and 2D8 (Figure 1) . Therefore, we conclude that, although 1D1 and 2D8 tend to have a higher affinity for apo B in VLDL than in LDL, the epitopes for 1D1 and 2D8 are expressed on fewer VLDL than LDL, but their relative number increases with increasing density.
These observations also yield another conclusion, namely that VLDL apo B is structurally heterogeneous because a very large proportion of VLDL do not express the epitopes for 1D1 and 2D8, a phenomenon independent of the antibody affinities as discussed above. Tsao and colleagues 50 have also observed that some of their Mabs against apo B had a higher affinity for VLDL and IDL apo B than for LDL apo B, but they did not evaluate whether the epitopes for these Mabs were expressed on a greater proportion of VLDL than LDL. Another possible interpretation for the existence of VLDL negative for 1D1 and 2D8 is the existence of VLDL rich in apo C, where the presence of these apolipoproteins interfere with epitope accessibility.
The proportion of lipoproteins expressing the 4G3 epitope, which is exclusively on apo B-100 and mapped between residues 2980 and 3080 (Figure 3) , also increased progressively as the density of the apo B-containing lipoproteins increased; however the affinity of 4G3 for the different lipoprotein subtractions did not change, as indicated by its similar Ka for these subtractions (Table 8) and by the similar immunoreactivity of these subtractions in the competitive RIA (Figure 2) . Therefore, based on these results, we conclude: First, the relative number of lipoprotein particles expressing the 4G3 epitope increases with the hydrated density of the lipoproteins; second, in the range of VLDL, to LDL 2 , the conformation of apo B at the site of the epitope for 4G3 does not change with the protein-to-lipid ratio of the apo B-containing lipoproteins or with the progressive increase in the cholesteryl ester-totriglyceride ratio in these lipoproteins. Thus, it would appear that if the 4G3 epitope is expressed in a given particle, it assumes an optimal conformation for interaction with the antibody. This implicit and necessary conclusion is somewhat surprising because we had shown earlier that the epitope for 4G3 is not expressed on delipidated and solubilized apo B but can be expressed upon the association of apo B with a lipid structure that has a hydrophobic core, such as cholesteryl esters. 52 This requirement of the 4G3 epitope for an interaction of apo B with hydrophobic lipid does not contradict the present conclusion that the conformation of the protein at this site is relatively constant in lipoproteins with varying ratios of neutral lipids to apo B, but indicates that, in the studied range of VLDL, to LDL 2 , this ratio and the nature of hydrophobic lipids, triglycerides, or cholesteryl esters, are sufficient to insure an optimum conformation of this site.
The antigenic determinants for 3A8 and 5E11, which are also exclusive to apo B-100 and are mapped between residues 3441 and 3568 (Figure 3) , have similar properties but are different from all the others in several respects. These epitopes are expressed on fewer VLDL,, VLDL 2 and VLDL 3 than any other epitopes, but like the others, the percentage of lipoproteins that expresses these epitopes increases with increasing density of the lipoproteins (Tables  3 and 4 ). In addition, it is clear that the affinity of 3A8 and 5E11 for their respective epitopes changes greatly as a function of the hydrated density of the lipoproteins. In the competitive RIA, there is a continuous and highly significant increase in the immunoreactivity of the lipoprotein fractions from VLDL, to LDL, with both 3A8 and 5E11, results that are distinctly different from all the other Mabs (Figures 1 and 2) : VLDL, are about 10-fold less immunoreactive than the LDL subtractions, and the immunoreactivity appears to plateau with lipoproteins in the range of LDL and does decrease again (as we have shown earlier) in the densest LDL particles found in hyperapobetalipoproteinemia. 20 Likewise, the Ka of 3A8 for apo Bcontaining lipoproteins increases progressively as the hydrated density of lipoproteins increases from VLDL, to LDL 2 ( Table 8 ). The studies reported here, therefore, corroborate and extend the observations of Tikkanen et al. 54 who noted that the binding affinity of their anti-apo B Mabs with VLDL subtractions increased with increasing density and that this included two Mabs that partially inhibit binding to the LDL receptor.
Our results demonstrate that the epitopes for 3A8 and 5E11 are truly conformational antigenic determinants, perhaps epitopes constituted by aminoacid residues that are not adjacent on the primary sequence of apo B, but whose respective positions change in proportion with the hydrated density characteristic of each of the apo Bcontaining lipoproteins. However, because the changes in hydrated density are the results of multiple processes resulting from or accompanying the lipolytic cascade of VLDL, it is not possible at this stage to identify the exact cause of the progressive modification in apo B conformation at the sites for 3A8 and 5E11. This modification may result directly from the decrease in particle size or from more complex mechanisms of changes in lipid composition, such as the increase in the cholesteryl ester-totriglyceride ratio. Further experiments are needed to clarify this point.
Because the epitopes for 3A8 and 5E11, which have been mapped between residues 3441 and 3568 ( Figure  3) , are probably close to the sequence 3352 to 3371, which is rich in basic aminoacids and which has been proposed as a putative binding site for the LDL receptor, 53 and because the reaction of 3A8 and 5E11 at their epitopes totally inhibits the binding of LDL to its receptor, 11 we predict that the same modification of apo B conformation that accompanies the increase in hydrated density causes both the increased immunoreactivity at epitopes 3A8 and 5E11 and the increased reactivity of the receptor binding site. Indeed, while there is much evidence to show that the receptor binding affinity of apo B increases gradually with the increase in hydrated density of the apo B-containing lipoproteins, 810 ' 1516 the results presented here on the increasing affinity of 3A8 and 5E11 for their epitopes constitute direct evidence of the evolution of apo B conformation as a function of density at sites close to the receptor binding sites. To document the theory that the denser lipoproteins do bind with more affinity with the apo B/E receptor, we have studied the binding of the lipoprotein subclasses of two of the patients with the LDL receptor of human fibroblasts in culture. As expected from the results of others, 1516 the ability of VLDL,, VLDL 2 , and VLDL 3 to compete with a control labeled LDL for binding to the receptor did not change significantly (Table 9 ). In contrast, when the same lipoproteins were first reacted with Mab 1D7, which blocks the interaction of apo E with the receptor, 39 the ability of these lipoproteins to bind to the LDL receptor exclusively via their apo B increased progressively as the density increased from VLDL, to IDL+LDL, ( Table 9 ).
The results reported here indicate that, while there is a continuum in the modification of apo B structure with lipolysis and lipid transfer, all domains are not equally affected as evidenced by the immunoreactivity of different epitopes and that specific changes in conformation occur in the vicinity of the LDL receptor binding site. We propose specifically that the changes in conformation that affect the region of residues 3441 to 3568, increase both the affinity of Mabs 3A8 and 5E11 with their epitopes and the affinity of apo B for the LDL receptor. In that respect, it is important to note that in the transformation of VLDL, to LDL, the greatest relative increase in the proportion of lipoproteins expressing specific epitopes has been noted for those reacting with Mabs 4G3, 3A5, and 5E11; that is, those close to the receptor binding site. Further studies are required to map these epitopes more accurately and by guest on November 10, 2017 http://atvb.ahajournals.org/ Downloaded from to define more precisely the changes in conformation that modulate the affinity of apo B with its receptor.
